BioSpace News Archive

Q2 revenue increases 45% YoY to US$25.0 million

BioInvent International AB will issue its interim report for the second quarter 2019 on Thursday August 22 at 8.30 a.m. CEST, followed by an audiocast with teleconference at 11.00 a.m. CEST, hosted by Martin Welschof, CEO and members of the management team.

Eli Lilly and Company is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at transforming inflammatory bowel disease care.

AstraZeneca and Merck’s LYNPARZA, When Added to Standard-of-Care Bevacizumab, Significantly Reduced the Risk of Disease Progression or Death in Women Who Responded to Platinum-Based Chemotherapy

Emmaus Life Sciences, Inc. announced that the company’s Sideline Sickle Cell campaign, led by Emmy Award-winning NFL broadcaster Solomon Wilcots, will host a sickle cell disease community town hall in South Florida to raise awareness for the rare disease and discuss current and future therapeutics.

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced updated clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA’s platform immunotherapy targeting tumor-initiating cells.

Regeneron Pharmaceuticals, Inc. announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 antibody, in patients with homozygous familial hypercholesterolemia.

Correvio Pharma Corp. reported financial results for its second quarter ended June 30, 2019 and commented on recent accomplishments and plans.

D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc. and Theraly Fibrosis Inc., announced that it has completed a $137.1 million Series B round of financing from U.S. and Korean investors.

Renovacor, Inc announced the successful completion of an $11 million Series A financing co-led by Novartis Venture Fund, Broadview Ventures, and BioAdvance, and joined by New Leaf Venture Partners and Innogest Capital.